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Switching Signals On or Off Minireview
by Receptor Dimerization
mechanisms (Thomas and Brugge, 1997). Receptor
PTKs are comprised of an extracellular ligand-binding
domain, a single transmembrane domain, and a cyto-
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Howard Hughes Medical Institute plasmic portion containing the catalytic core, as well as
regulatory sequences. Several families of growth factorsUniversity of California, San Francisco
San Francisco, California 94143-0795 induce receptor dimerization by virtue of their dimeric
nature (e.g., PDGF). Monomeric growth factors, such as#Department of Pharmacology and
the Skirball Institute EGF, contain two binding sites for their receptors and,
therefore, can cross-link two neighboring EGF receptorsNew York University Medical Center
New York, New York 10016 (Lemmon et al., 1997). Yet, another family of growth
factors (FGF) bind to their receptors monovalently but
utilize accessory molecules to facilitate the formationMany extracellular signals transduce their cellular re-
sponses by regulating the tyrosine phosphorylation of of multimeric ligand±receptor complexes (reviewed by
Schlessinger, 1997). Receptor dimerization is essentialtarget proteins. Protein tyrosine kinases (PTKs) can be
divided into two classes of enzymes: receptor PTKs that for stimulation of the intrinsic catalytic activity and for
the autophosphorylation of growth factor receptors.span a membrane, and cytoplasmic PTKs. Conversely,
the dephosphorylation reaction of tyrosine phosphory- Moreover, receptor PTKs are able to undergo both
homo- and heterodimerization. Ligand-induced recep-lated proteins is carried out by protein tyrosine phospha-
tases (PTPs). PTPs can also be divided into two classes tor oligomerization has been established as a universal
mechanism for the activation of hormone and growthof enzymes: transmembrane receptor-like PTPs, and
cytoplasmic PTPs. Considerable progress has been factor receptors, lymphokine receptors, T-cell recep-
tors, and B-cell receptors, as well as many other familiesmade in understanding the regulation and activation of
PTKs. In contrast, very little is known about the regula- of cell surface receptors (Lemmon and Schlessinger,
1994). Since eachprotomer in such oligomers can recruittion and activity of PTPs, although a few clues are
emerging from recent structural and functional studies. a distinct complement of signaling proteins, receptor
oligomerization not only leads to increased catalyticSome of the paradigms learned from studying the PTKs
have guided us well in our efforts toward understanding function but also provides a simple mechanism for gen-
eration of signal diversity (Lemmon and Schlessinger,PTP function. However, some surprising differences are
also suggested. 1994).
The mechanism by which receptor PTK dimerizationRegulation of Protein Tyrosine Kinases
It is now well established that receptor PTKs are acti- stimulates catalytic activity is not yet fully understood,
but a picture from the available data is emerging (Hub-vated by an intermolecular mechanism (Lemmon and
Schlessinger, 1994). Cytoplasmic PTKs, on the other bard et al., 1998). Central to the activation of most PTKs
is the phosphorylation of one or more tyrosines withinhand, are activated by both intra- and intermolecular
Figure 1. Models for the Regulation of Re-
ceptor PTK and Receptor PTP Activities by
Dimerization
Dimerization stimulates receptor PTK activ-
ity. Monomeric receptor PTKs exhibit weak
basal activity (Inactive). Ligand-induced re-
ceptor dimerization increases the local con-
centration of the kinase domain leading to
more efficient transphosphorylation of tyro-
sine residues in the mobile activation loop (A
loop). Substrate and ATP compete with the
A loop in the ªclosedº conformation (red). The
catalytic domain with ªopenº conformation
(green) on the other hand, permits ATP bind-
ing and allows transphosphorylation to pro-
ceed leading to stimulation of kinase activity
(Active). Activated PTK transphosphorylates
additional tyrosine residues that function as
binding sites for signaling proteins.
Dimerization inhibits receptor PTP activity.
Monomeric receptor PTPs exhibit enhanced
catalytic activity (Active). For most receptor
PTPs the membrane-proximal PTP domain is
catalytically active while the distal PTP do-
main has a regulatory role. Ligand-induced
receptor dimerization facilitates dimerization
of the two membrane-proximal PTP domains. Inhibitory wedge sequences from each phosphatase domain will interact with the catalytic
domain of the other protomer. These interactions will prevent substrate from binding to the catalytic core and thus lead to inhibition of PTP
activity (Inactive). Receptor PTP mutants in the inhibitory wedge sequence that binds to the catalytic core are not inhibited by dimerization.
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the activation loop (A loop) in the catalytic domain. One
plausible mechanism is that dimerization stabilizes a
conformation of the catalytic domain with the A loop in
an ªopenº conformation. This conformation of the active
site accommodates ATP and substrate binding, en-
abling transphosphorylation of the A loop, stabilizing
the catalytic domain in an active conformation. An al-
ternative mechanism is that receptor dimerization in-
creases the local concentration of the kinase domain
leading to more efficient transphosphorylation of ty-
rosine residues within the A loop between two neighbor-
ing protomers. There is good evidence from the crystal-
lographic temperature factors that the A loop of the
unphosphorylated kinase domains of insulin and FGF
receptor are very mobile, and therefore the A loop
probably exists in different conformations (Hubbard et
al., 1998). While substrate and ATP will compete with
the A loop in the ªclosedº conformation, the ªopenº
conformation of the A loop will accommodate ATP bind-
ing and would allow transphosphorylation to proceed
(Figure 1). Transphosphorylation of three tyrosine resi-
dues in the A loop of the insulin receptor was shown to
stabilize the phosphorylated A loop in an ªopenº confor-
mation enabling access to ATP and substrates and per-
miting phospho-transfer catalysis from MgATP to sub-
strate proteins (Hubbard et al., 1998).
Similar principles appear to hold for nonreceptor PTKs
Figure 2. Autoinhibition of Cytoplasmic PTK and PTPas well. The catalytic activity of most cytoplasmic PTKs
SH3- and SH2-mediated autoinhibition of Src. The PTK domain ofis also activated by a transphosphorylation of a tyrosine
Src is maintained in an inactive state by means of intramolecularresidue in their A loops. However, the mechanisms in-
interactions mediated by the SH3 and SH2 domains. The SH3 do-volved in this transautophosphorylation represent varia-
main binds to proline-rich sequence in the SH2-kinase linker andtions on the dimerization paradigm. Some kinases such
the SH2 domains bind to pTyr527 in the C-terminal tail of Src, thus
as the Jak family and Lck of the Src family are activated maintaining the enzyme in an inactive state (ªclosedº). The tyrosine
by homo- or heterodimerization of their noncovalently kinase activity of Src can be stimulated by binding of target proteins
associated receptors (i.e., cytokine receptors and the containing proline-rich sequences to the SH3 domain, by binding
of phosphotyrosine-containing sequences to the SH2 domain, orCD4/CD8 coreceptors, respectively) (Thomas and Brugge,
by dephosphorylation of pTyr527. Autoinhibition is released in the1997). Other cytoplasmic PTKs are activated through
ªopenº conformation enabling kinase activation by transauto-transphosphorylation events involving receptor or other
phosphorylation of the A loop.families of cytoplasmic kinases. For instance, Src ki-
SH2-mediated autoinhibition of Shp2. The tyrosine phosphatase
nases have frequently been implicated in the activation Shp2 is maintained in an autoinhibited state by means of intramolec-
of the Fak, Syk, and Btk families of cytoplasmic PTKs. ular interactions between the N-SH2 domain and the catalytic cleft
The signaling events that drive the interactions of these of the PTP domain. It was shown that a loop of the SH2 domain
occupies the catalytic cleft, thus preventing access of substrateskinases are still being characterized but often involve
to the catalytic core (ªclosedº). Binding of specific phosphotyrosine-the recruitment of one of the substrate kinases to the
containing sequences to the N-SH2 domain will release the autoin-plasma membrane or another cellular location where it
hibition and render Shp2 in an active conformation (ªopenº).is brought into proximity with a Src family kinase that
is poised to phosphorylate it. In the broadest view, such
transphosphorylation events occur between homo- or
SH2 domain binds to pTyr527 in the C-terminal end of Src.heterodimers of cytoplasmic PTKs.
Several studies demonstrated that the tyrosine kinaseAlthough the function of Src kinases can be activated
activity of Src can be stimulated by the binding of targetby receptor-mediated events that lead to A-loop trans-
proteins containing proline-rich sequences to the SH3phosphorylation, as in the case of CD4/CD8 and Lck,
domain. Src PTK activity can be also stimulated by bind-another level of regulation for these kinases involves
ing of phosphotyrosine-containing sequences to theintramolecular interactions mediated by their SH2 and
SH2 domain or by dephosphorylation of pTyr527 (FigureSH3 domains. It has long been appreciated that a tyro-
2). Some studies have provided evidence that receptorsine near the C termini of Src kinases functions as a
PTPs are responsible for the dephosphorylation of thisnegative regulatory siteof phosphorylation (Thomas and
C-terminal tyrosine, as in the case of CD45 and Lck (seeBrugge, 1997). The recent crystal structures of inactive
below). The opening up of the Src kinases via suchSrc kinases have revealed the nature of the intramolecu-
interactions renders it in an activatable conformation,lar negative regulatory mechanism (Xu et al., 1997). The
poised to have its A loop phosphorylated through anPTK domain of Src is maintained in an inactive state
intermolecular interaction with another Src molecule.through two different intramolecular interactions with
Thus, PTKs have provided us with paradigms wherebyits SH3 and SH2 domains. While the SH3 domain binds
inter- and intramolecular binding events can regulateto a short proline type-II helix in a region connecting the
SH2 domain to the PTK domain (SH2-kinase linker), the their catalytic functions.
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Regulation of Tyrosine Phosphatases: this critical function is provided by the findings that
CD45-deficient T and B cells have diminished antigenCommon Themes
Much less is known regarding the regulation of function receptor±induced tyrosine phosphorylation as well as
hyperphosphorylation of the C-terminal negative regula-of the PTPs. Unlike the PTKs, the catalytic domains of
PTPs do not require posttranslational modifications to tory tyrosine in the Src kinases Lck and Fyn. These
PTKs are required in initiating the events involved inmaintain their activities. In fact, the catalytic functions
of these enzymes are generally regarded to be much TCR signal transduction. The ability of several different
membrane-targeted forms of the CD45 cytoplasmic do-greater than that of the PTKs. Nevertheless, there are
sufficient data to suggest that the functions of these main, including the EGFR-CD45 chimera, to restore TCR
signal transduction suggests that the CD45 extracellularenzymes are rigorously controlled by changing the local-
ization of these enzymes within the cell and through and transmembrane domains are not required for spe-
cific interactions with the TCR or substrates (Desai etnoncovalent means of regulating catalytic function in-
volving inter- and intramolecular events. Some of these al., 1993). On the other hand, a role for the extracellular
domain was suggested when EGF was added to theseregulatory mechanisms may be quite analogous to the
blueprint of the controls in place for PTKs. reconstituted cells. Quite remarkably, dimerization of
the chimera, and specifically dimerization of its cyto-A large number of transmembrane PTPs have been
identified (Fashena and Zinn, 1995; Denu et al., 1996). plasmic domain, impaired its functional ability to support
TCR signaling. Thus, these observations suggest thatMany of these enzymes are expressed in a tissue-spe-
cific manner. Most have cytoplasmic domains con- dimerization of a membrane PTP inhibits its function.
This stands in marked contrast to the activating functiontaining tandem PTP domains, the membrane-proximal
domain having greater and in some cases all of the that dimerization plays for PTKs.
An explanation for this intriguing effect of dimerizationcatalytic activity. The functional importance of the dual
PTP domain structure remains an unresolved puzzle, is offered by recent structural and mutational studies.
The structure of the membrane-proximal phosphatasealthough some evidence suggests that the second do-
main may have a regulatory function. The transmem- domain of another transmembrane PTP, PTPa, is quite
typical of other phosphatase domains (Bilwes et al.,brane PTPs are likely to function as receptors since their
extracellular domains differ considerably, suggesting 1996). However, in two distinct crystal packing lattices,
this PTP domain forms a symmetrical dimer. The dimerunique ligand binding specificities. In most cases, the
physiologic ligand is not known. However, PTP k, m, and interface is based on a wedge-like structure, formed
from sequences just N-terminal of theprototypical phos-l have been shown to form homotypic interactions with
like molecules on other cells (Fashena amd Zinn, 1995). phatase domain, interacting with the catalytic site of
the other partner in the dimer. If this interaction wereIn addition, the extracellular domain of RPTP-b has been
shown to bind specifically to the neuronal receptor Con- mimicked by dimerization in vivo, this wedge would be
predicted to block access of substrate to the catalytictactin (Peles et al., 1995). However, ligand binding does
not change the catalytic activity or have an obvious site. Sequences homologous to the wedge are present
N-terminal to the membrane-proximal phosphatase do-functional impact. Relocalization of transmembrane PTPs
has been suggested to be the role of such interactions. main of other transmembrane PTPs, including CD45,
but are not found adjacent to the distal phosphataseHowever, one of the difficulties in understanding the
role of ligand binding in regulating these transmembrane domains or in cytoplasmic PTPs. The tip of this putative
wedge in CD45 was recently mutated, abolishing thePTPs is the paucity of information about their biologi-
cal functions. One exception is the CD45 transmem- inhibitory effects of EGF on the function of the EGFR-
CD45 chimera (Majeti et al., 1998), suggesting that CD45brane PTP.
Receptor PTP Activity Is Inhibited by Dimerization function may be negatively regulated by its physiologic
ligand. Ligand-induced CD45 dimerization would blockCD45 is a dual PTP domain transmembrane molecule
expressed on all nucleated hematopoietic cells (Trow- the catalytic site in CD45, thereby preventing substrate
accessibility and inhibiting TCR function. This could bebridge and Thomas, 1994). Tightly regulated alternative
splicing of exons 4±6 leads to the cell- and activation- part of a negative feedback loop involving a physiologic
ligand, which remains to be identified, that is producedspecific expression of various isoforms of CD45. These
three exons encode many O-linked glycosylation sites during the course of an immune response. Production
of such a ligand could also be temporally linked to thethat add substantial size and negative charge to the
extracellular domain, suggesting differences in ligand change in the highly regulated alternative splicing of
CD45 that leads to the expression of a distinct CD45specificities of the various isoforms. However, specific
ligands for CD45 have not been identified. This led to isoform on activated T cells. An intriguing possibility is
that ligand-induced dimerization of other transmem-the use of a heterologous ligand-binding domain to
study the effects of ligand binding on CD45 function. brane PTPs will likewise lead to inhibitory effects via
blockade of their catalytic site by an inhibitory wedge.The extracellular and transmembrane domains of the
EGF receptor were used in place of those of CD45. The However, caution must be exercised in extrapolating
these data to all transmembrane PTPs, since at leastfunction of this EGFR-CD45 chimera has provided some
clues regarding how ligands might regulate the function one other crystal structure of the membrane-proximal
PTPm fails to recapitulate a similar dimer interface (Hoff-of transmembrane PTPs (Desai, et al., 1993).
The expression of CD45 as well as its catalytic func- mann et al.,1997). However, in recent studies the second
catalytic domain of receptor PTPd could bind to andtion is required for normal lymphocyte development and
antigen receptor signal transduction function (Kishihara inhibit the first catalytic domain of this phosphatase. The
inhibition thought to be caused by receptor dimerizationet al., 1993; Desai et al., 1994). The best explanation for
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was shown to be mediated by the inhibitory wedge se- kinases (Src and Tec families); in both cases, binding
to substrate ªopensº the ªclosedº autoinhibited statequence in the membrane-proximal PTP domain (Wallace
of these two classes of enzymes engaged in oppositeet al., 1998). Thus, transmembrane PTPs may be regu-
functions (Figure 2).lated by ligand in the exact opposite way from receptor
Thus, common themes in the molecular mechanismsPTKs: instead of activation in the case of PTKs, ligand-
underlying PTK and PTP regulation are emerging. It isinduced PTP dimerization inhibits these molecules by
not very surprising that receptor and cytoplasmic PTKsblocking access to their catalytic sites (Figure 1).
utilize similar mechanisms to induce catalytic function.PTP regulation by blockade of the catalytic site may
Some form of dimerization and A-loop tyrosine phos-be a general mechanism for the regulation of this class
phorylation play dominant roles in their regulation. How-of enzymes, as evidenced by a similar theme developing
ever, in the case of dimerization of receptor PTPs, inhibi-from work on cytoplasmic PTPs. However, instead of
tion of catalytic function is a new paradigm to beintermolecular blockade of the catalytic site, intramolec-
considered. Surprising analogies are also seen in theular blockade may be the principal mode of regulation.
case of the cytoplasmic enzymes, and autoinhibition viaIn addition to their phosphatase domains, cytoplasmic
intramolecular interactions involving protein interactionPTPs often contain other protein interaction domains.
domains is a theme shared by the PTKs and PTPs. Inter-Most work has focused on the ability of these protein
actions with potential substrates may contribute to theinteraction domains to target the catalytic domain to its
induction of catalytic activity for both classes of en-potential substrate. Considerable work on this theme
zymes. Finally, whereas there were few clues regardinghas developed for the dual SH2 domain containing
the mode of regulation of PTP catalytic function, block-PTPases SHP-1 and SHP-2 (i.e., SHP-2 targeting to the
ade of the catalytic site may be important and sharederythropoietin receptor and SHP-1 targeted to inhibitory
in the regulatory scheme used by other members of thereceptors on lymphoid cells) (Neel and Tonks, 1997).
PTP family.However, the recently solved crystal structure of SHP-2
reveals a surprising and unanticipated role for the
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